
PMC:7519301 / 5854-7256
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T22 | 763-766 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T23 | 954-964 | Body_part | denotes | nucleotide | http://purl.org/sig/ont/fma/fma82740 |
T24 | 1078-1081 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
T25 | 1130-1140 | Body_part | denotes | nucleotide | http://purl.org/sig/ont/fma/fma82740 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T54 | 29-37 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T55 | 29-33 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T56 | 365-373 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T57 | 448-457 | Disease | denotes | influenza | http://purl.obolibrary.org/obo/MONDO_0005812 |
T58 | 610-618 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T59 | 610-614 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T60 | 910-918 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T61 | 910-914 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T62 | 1026-1034 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T63 | 1026-1030 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T64 | 1381-1389 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T65 | 1381-1385 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T64 | 11-12 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T65 | 43-44 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T66 | 203-208 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T67 | 767-774 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T68 | 795-796 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T69 | 980-981 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T70 | 1082-1089 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | viruses |
T71 | 1103-1111 | http://purl.obolibrary.org/obo/CLO_0001040 | denotes | 1 × 10−5 |
T72 | 1218-1220 | http://purl.obolibrary.org/obo/CLO_0050510 | denotes | 18 |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T21 | 209-217 | Chemical | denotes | antigens | http://purl.obolibrary.org/obo/CHEBI_59132 |
T22 | 954-964 | Chemical | denotes | nucleotide | http://purl.obolibrary.org/obo/CHEBI_36976 |
T23 | 1130-1140 | Chemical | denotes | nucleotide | http://purl.obolibrary.org/obo/CHEBI_36976 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
143 | 29-39 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
144 | 610-620 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
145 | 776-789 | Species | denotes | coronaviruses | Tax:11118 |
146 | 910-920 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
147 | 1026-1034 | Species | denotes | SARS-CoV | Tax:694009 |
148 | 1381-1391 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
149 | 448-457 | Species | denotes | influenza | Tax:11309 |
150 | 299-307 | Disease | denotes | infected | MESH:D007239 |
151 | 365-373 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T39 | 0-123 | Sentence | denotes | Developing a vaccine against SARS-CoV-2 is a high priority for preventing and mitigating future waves of the pandemic (14). |
T40 | 124-320 | Sentence | denotes | Vaccine candidates typically include an insert that corresponds to one or more virus antigens, either derived computationally or from one or multiple sequence(s) sampled from infected individuals. |
T41 | 321-532 | Sentence | denotes | The first viral sequence derived during the COVID-19 outbreak, Wuhan-Hu-1 (available from the Global initiative on sharing all influenza data, GISAID, accession EPI_ISL_402125), was published on January 9, 2020. |
T42 | 533-744 | Sentence | denotes | As many vaccine programs were initiated at that time, it is likely that this SARS-CoV-2 sequence, sampled in December 2019 in Wuhan, China, is the foundation for many vaccine candidates currently in development. |
T43 | 745-871 | Sentence | denotes | Compared to other RNA viruses, coronaviruses have a more complex molecular machinery resulting in higher replication fidelity. |
T44 | 872-1156 | Sentence | denotes | Early evolutionary rate estimates for SARS-CoV-2 were ∼1 × 10−3 substitutions per nucleotide per year (15), a rate comparable to that observed during the SARS-CoV-1 outbreak (16) and in the range for other RNA viruses (1 × 10−3 to 1 × 10−5 substitutions per nucleotide per year) (17). |
T45 | 1157-1402 | Sentence | denotes | While the evolutionary rate is likely to decrease over time (18), it is important to monitor the introduction of any mutation that may compromise the potential efficacy of vaccine candidates derived from the first available SARS-CoV-2 sequences. |